Medindia

X

Aratana Therapeutics to Report First Quarter 2016 Financial Results

Friday, April 15, 2016 Corporate News J E 4
Advertisement

LEAWOOD, Kan., April 14, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, will host a live conference call on Friday, May 6, 2016 at 8:30 a.m. ET to discuss financial results for the first quarter ending March 31, 2016.

Interested participants and investors may access the audio webcast or use the conference call dial-in:

     1 (866) 364-3820 (U.S.)      1 (855) 669-9657 (Canada)      1 (412) 902-4210 (International)

A replay of the first quarter results teleconference will be available the same day of the event by approximately 11 a.m. ET and an audio webcast will be accessible for 90 days in the Aratana Investor Room. For a replay of the call, use the below dial-in and conference ID 10084748:

     1 (877) 344-7529 (U.S.)      1 (855) 669-9658 (Canada)      1 (412) 317-0088 (International)

About Aratana TherapeuticsAratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative pharmaceutical products for dogs and cats. Aratana believes that it can leverage the investment in the human pharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The Company has multiple products approved by the Food and Drug Administration's Center for Veterinary Medicine or licensed by the United States Department of Agriculture. The Company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious, unmet or underserved medical needs.  Aratana believes providing innovative options to veterinarians and pet owners will help manage pets' medical needs safely and effectively, result in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Contacts For investor inquires: Craig Toomanctooman@aratana.com (913) 353-1026

For media inquiries: Rachel Reiffrreiff@aratana.com (913) 353-1050

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aratana-therapeutics-to-report-first-quarter-2016-financial-results-300251872.html

SOURCE Aratana Therapeutics

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Once-a-Day Epilepsy Drug May Prevent Seizures as W...
S
QIAGEN Launches Streamlined Bioinformatics for RNA...